NCT04963738View on ClinicalTrials.gov

A Study of JNJ-73763989 in Adult Participants With Renal Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 22, 2021

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions
Renal Impairment
Interventions
DRUG

JNJ-73763989

JNJ-73763989 will be administered as a single SC injection.

Trial Locations (1)

24105

CRS Clinical Research Services Kiel GmbH, Kiel

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04963738 - A Study of JNJ-73763989 in Adult Participants With Renal Impairment | Biotech Hunter | Biotech Hunter